Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis

• Main Authors: Stefan Blankenberg, Dominique Stengel, Hans J. Rupprecht, Christoph Bickel, Ju¨rgen Meyer, François Cambien, Laurence Tiret, Ewa Ninio
• Format: Article
• Language: English
• Published: Elsevier 2003-07-01
• Series: Journal of Lipid Research
• Subjects: inflammation; atherosclerosis; platelet-activating factor
• Online Access: http://www.sciencedirect.com/science/article/pii/S0022227520311019

Inflammation underlies both onset and perpetuation of atherosclerosis. Plasma lipoproteins transport the platelet-activating factor-acetylhydrolase (PAF-AH) with potentially anti-inflammatory activities. Our aim was to determine whether PAF-AH activity was associated with inflammatory markers and with coronary artery disease (CAD). PAF-AH activity and a panel of inflammatory mediators were measured in plasma of 496 patients with CAD and in 477 controls; 276 patients presented with stable angina pectoris and 220 with acute coronary syndrome (ACS). Individuals within the highest quartile of PAF-AH activity had an 1.8-fold increase in CAD risk [95% confidence interval (CI), 1.01 to 3.2; P = 0.048] compared with those in the first quartile (adjusted for clinical and metabolic factors). When excluding individuals receiving statin and angiotensin-converting enzyme-inhibitor medication, individuals within the highest quartile of PAF-AH activity revealed a 3.9-fold increase in CAD risk (95% CI, 2.0 to 7.7; P < 0.0001). In these subjects, the plasma PAF-AH activity increased gradually in stable angina and in ACS both in men (P < 0.0001) and in women (P < 0.001), as compared with controls.No correlation was found between PAF-AH levels and those of common markers of inflammation. This study and the previous ones raise the important issue of whether PAF-AH is simply a marker of risk or directly promotes atherosclerosis.